CJC-1295 is a synthetic analogue used in laboratory studies involving growth-hormone–releasing hormone (GHRH) pathway models. Two research formats are available: a standard GHRH analogue and a DAC-modified version designed to evaluate extended-duration signaling behavior in controlled experimental environments. Supplied as a lyophilized powder, this material supports consistent preparation and reproducible laboratory conditions.
Lyophilized powder supplied in standard laboratory vials.
Not for injection. Not for clinical or therapeutic use.
Features:
- Two Research Formats: Standard CJC-1295 and DAC-modified CJC-1295 for comparative signaling studies.
- Laboratory-Ready Lyophilized Powder: Supports accurate measurement and controlled reconstitution.
- Stable Storage Profile: Suitable for refrigerated conditions after reconstitution.
Research Notes:
- GHRH Pathway Investigation: Utilized in model systems studying peptide–receptor activation dynamics.
- Duration-of-Action Models: DAC modification enables examination of extended peptide persistence in controlled environments.
- Comparative Studies: Allows evaluation of structural differences between DAC and non-DAC analogues within signaling research frameworks.
CJC-1295 provides researchers with a reliable tool for examining GHRH-related signaling in laboratory model systems. Store in a cool, dry place. This compound is intended solely for laboratory research use only.
🔬 Interested in the Science?
Review pathway models, structural comparisons, and analytical findings related to GHRH analogues.
🔬 Research Applications
- GHRH pathway signaling studies
- Persistence and duration-of-action peptide models
- Structure–function research comparing modified and unmodified analogues
🧪 Molecular Details
- CAS Number: 863288-34-0
- Molecular Formula: C165H271N47O46
- Molecular Weight: 3647.9 g/mol
- Form: Lyophilized Powder
- Appearance: White Powder
- Storage: Store in a cool, dry place.
CJC-1295 – Growth and Performance Peptide FAQ
This FAQ provides structured technical information regarding the laboratory application, molecular variations, and experimental handling of CJC-1295 for controlled research environments.
1. What is CJC-1295 used for in laboratory research?
CJC-1295 is used in controlled studies involving growth-hormone–releasing hormone (GHRH) pathways. Researchers apply it in model systems to investigate peptide–receptor interactions, signalling dynamics, and hormone-related biochemical responses.
2. What is the difference between CJC-1295 DAC and non-DAC versions?
The DAC (Drug Affinity Complex) version is modified to extend the compound’s duration of activity in experimental models, while the non-DAC version represents the standard analogue with a shorter activity profile. This allows researchers to compare signalling persistence and response over time.
3. Why is CJC-1295 supplied as a lyophilised powder?
The lyophilised format improves stability and enables precise reconstitution. This supports accurate dosing and consistency across laboratory experiments, which is critical for reproducible results.
4. What types of studies involve CJC-1295 in research settings?
CJC-1295 is commonly used in GHRH pathway analysis, structure–function research, and duration-of-action studies. It is particularly relevant in experiments examining how peptide modifications affect signalling behaviour.
5. How should CJC-1295 be stored after reconstitution?
After reconstitution, CJC-1295 should be stored under refrigerated conditions to maintain stability. Proper handling and storage are essential to preserve the compound’s integrity during experimental use.



